Breast Cancer Treatment Without Surgery — in Hyderabad

Neoadjuvant chemotherapy is given in cycles — typically every 3 weeks — through a drip (IV infusion) at an CION outpatient clinic. Each session lasts 2 to 4 hours, depending on the medicines used. Most patients complete 6 to 8 cycles over 4 to 6 months. You go home the same day. You will have a blood test before every cycle to make sure your counts are safe to proceed.

Common side effects include fatigue, nausea, hair thinning, and reduced immunity. Your CION team prescribes anti-nausea medicines, monitors your blood count at each visit, and adjusts the plan if side effects become difficult. Many patients continue working or managing daily life during chemotherapy — it depends on the cycle timing and your response.

After completing the cycles, you have a repeat scan and clinical examination to measure the response. If the tumour has shrunk adequately, surgery proceeds with a smaller operation. The CION surgical oncologist and medical oncologist review the response together before planning the next step.

Hormone-blocking therapy for breast cancer is usually taken as a tablet once a day, at home. It is not chemotherapy — it does not cause hair loss or make you feel deeply unwell. Most patients can continue normal daily life, including work, while taking it.

The duration is long — typically 5 years for lower-risk patients, and up to 10 years for higher-risk patients. This is not a mistake: the protection against recurrence continues to build over years and lasts well beyond the treatment period. Stopping early significantly reduces the benefit, so CION's oncology team monitors you regularly to manage any side effects that might tempt you to stop — joint stiffness, hot flushes, and changes in bone density are the most common.

CION schedules a check-up every 3 to 6 months during hormone therapy. If you develop bone density loss, we manage it proactively with supplements and, when needed, medicines to protect bone strength. You are never left to manage side effects alone. For patients who cannot tolerate one class of hormone-blocking therapy, there are alternative options — your tumor board will switch you, not just stop treatment.

Targeted therapy for HER2-positive breast cancer is given by IV infusion — typically every 3 weeks — at the CION clinic. Each session is usually shorter than chemotherapy, often 30 to 90 minutes once the loading dose has been given. The medicines specifically block the HER2 protein on cancer cells, which means they cause fewer of the broad side effects associated with chemotherapy.

The most common side effects include mild fatigue, infusion reactions during the first session (which are carefully managed by the nursing team), and, rarely, effects on heart function. For this reason, your CION oncologist arranges an echocardiogram (heart scan) before starting and repeats it periodically during treatment. This is standard practice — not a sign of concern, but of careful monitoring.

In the neoadjuvant setting, targeted therapy is usually given together with chemotherapy for 4 to 6 months before surgery. In metastatic HER2-positive breast cancer, targeted therapy can be continued for as long as it is working, with regular scans to assess response. The CION medical oncologist and tumor board review your scans every 3 months to decide whether to continue, switch, or add to the regimen.

Immunotherapy for breast cancer works by removing a "brake" that cancer cells place on the immune system, allowing the body's own defences to recognise and attack the tumour. It is given by IV infusion, usually every 2 to 3 weeks, alongside chemotherapy — not instead of it. Sessions typically last 30 to 60 minutes for the immunotherapy component itself.

Eligibility is specific: immunotherapy in the breast cancer setting is used for selected patients with triple-negative breast cancer (ER-, PR-, HER2-). Your CION pathologist tests for relevant eligibility markers from your biopsy. Not all triple-negative patients qualify, and your tumor board will be honest about this — we do not recommend treatments that will not benefit you.

Side effects of immunotherapy are different from chemotherapy. The most important ones are immune-related — where the activated immune system can affect the lungs, bowel, liver, or skin. These are manageable when caught early, which is why CION monitors you closely. You are given a card listing warning symptoms to watch for between visits, and there is always someone to call.

Radiation therapy is delivered as short daily sessions — typically 10 to 25 minutes — Monday through Friday, over 3 to 6 weeks. You go home immediately after each session. The radiation is carefully planned using CT-based simulation so only the tumour bed (and, if needed, the lymph nodes) receives the dose, with surrounding healthy tissue protected as much as possible.

After a lumpectomy (breast-conserving surgery), radiation to the remaining breast tissue is standard — it is part of what makes a smaller operation as effective as mastectomy for local control. In some elderly patients with very small, hormone-sensitive tumours, radiation may be safely omitted if the patient is on hormone-blocking therapy and fully understands the small increase in local recurrence risk. This is a decision made by the tumor board with the patient, not assumed.

In stage 4 (metastatic) breast cancer, radiation is sometimes used to relieve pain from bone metastases or to treat a specific area of disease that is not responding to systemic treatment. This is called palliative radiation. It does not aim to cure but can significantly improve quality of life. CION's radiation oncologists discuss the goal of treatment clearly before any session begins.

In metastatic breast cancer — where cancer has spread beyond the breast to other organs — the goal of treatment shifts from cure to long-term control. Surgery on the original breast tumour is often not the first priority, and may not be needed at all, because the cancer in other parts of the body is what needs to be managed.

Treatment for metastatic breast cancer depends on the tumour biology. For hormone receptor positive disease, hormone-blocking therapy combined with targeted medicines that block tumour cell division is the standard first approach — and can control the cancer for years. For HER2-positive metastatic breast cancer, targeted therapy combinations have transformed outcomes significantly. For triple-negative metastatic disease, chemotherapy — with or without immunotherapy — is the main option.

CION's tumor board reviews every metastatic patient's case every 3 months, or sooner if symptoms change. The goal is the best possible quality of life alongside the longest possible disease control. Supportive care — nutritionist, psycho-oncologist, palliative care — is built into the plan from the beginning, not added later as an afterthought. You deserve both length and quality of life.